ZA200108326B - Protein/polypeptide-k obtained from momordica charantia and a process for the extraction thereof. - Google Patents
Protein/polypeptide-k obtained from momordica charantia and a process for the extraction thereof. Download PDFInfo
- Publication number
- ZA200108326B ZA200108326B ZA200108326A ZA200108326A ZA200108326B ZA 200108326 B ZA200108326 B ZA 200108326B ZA 200108326 A ZA200108326 A ZA 200108326A ZA 200108326 A ZA200108326 A ZA 200108326A ZA 200108326 B ZA200108326 B ZA 200108326B
- Authority
- ZA
- South Africa
- Prior art keywords
- polypeptide
- protein
- momordica charantia
- seeds
- insulin
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims description 51
- 108090000623 proteins and genes Proteins 0.000 title claims description 51
- 244000302512 Momordica charantia Species 0.000 title claims description 31
- 235000009811 Momordica charantia Nutrition 0.000 title claims description 31
- 238000000034 method Methods 0.000 title claims description 31
- 230000008569 process Effects 0.000 title claims description 26
- 238000000605 extraction Methods 0.000 title claims description 22
- 235000018102 proteins Nutrition 0.000 claims description 50
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 32
- 229940024606 amino acid Drugs 0.000 claims description 26
- 235000001014 amino acid Nutrition 0.000 claims description 25
- 150000001413 amino acids Chemical class 0.000 claims description 25
- 206010012601 diabetes mellitus Diseases 0.000 claims description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 15
- 235000013399 edible fruits Nutrition 0.000 claims description 11
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 11
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 9
- 241000196324 Embryophyta Species 0.000 claims description 8
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 7
- 239000000908 ammonium hydroxide Substances 0.000 claims description 7
- 239000012454 non-polar solvent Substances 0.000 claims description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 4
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 238000010956 selective crystallization Methods 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000011835 investigation Methods 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- 229930014626 natural product Natural products 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 60
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 36
- 108090001061 Insulin Proteins 0.000 description 30
- 102000004877 Insulin Human genes 0.000 description 30
- 229940125396 insulin Drugs 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 239000008280 blood Substances 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 24
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 9
- 239000000843 powder Substances 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 101001011741 Bos taurus Insulin Proteins 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 235000009815 Momordica Nutrition 0.000 description 6
- 241000218984 Momordica Species 0.000 description 6
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 4
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 4
- 229960002591 hydroxyproline Drugs 0.000 description 4
- 239000003791 organic solvent mixture Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- INLFWQCRAJUDCR-IQVMEADQSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane] Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 INLFWQCRAJUDCR-IQVMEADQSA-N 0.000 description 3
- 231100000749 chronicity Toxicity 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 229960004132 diethyl ether Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 3
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 229940120105 glynase Drugs 0.000 description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
- -1 methione Chemical compound 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 1
- 241000609103 Sarcophaga africa Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001632 homeopathic effect Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
PROTEIN/POLYPEPTIDE-K OBTAINED FROM MOMORDICA
CHARANTIA AND A PROCESS FOR TBE EXTRACTION THEREOF
This invention relates to a highly effective protein called “polypeptide-k”, extracted from Momordica charantia. This invention also provides a method for the extraction of said polypeptide-k from Momordica charantia. Further, the invention provides novel hypoglycaemic compositions employing the said extract, and useful in the treatment of diabetes mellitus.
Insulin has hitherto been commercially synthesised from the pancreas of animals and human insulin from E.Coli (Eli Lily, U.S.A). So far there is no commercial extraction of insulin / polypeptide-k from plant source.
Isolation of insulin from animal pancreas is open to objection due to the following reasons: 1. By killing 10,000 animals only one pound of pure insulin is obtained. - 2. It is not being sublingually administered. 3. If the pancreas are infected by some diseases there is always a probability of its being carried (if it is a virus) along with the insulin. 4. Human insulin can be synthesised from E.Coli which is expensive.
Hence, to obviate these and other drawbacks in conventional insulin extraction methods, scientists focussed on plant based products.
Co
Momordica 'charantia is a perennial herb of the family Cucurbitaceae, widely grown in Asia. The herb is endemic to tropical regions like India, S. Africa
Philippines, China and Burma. The species of Momordica found in western countries are different from the tropical - species in that, the plants differ in morphological and organoleptic properties. Various parts of this plant, especially 1 oo . ) EE ; AMENDED SHEET 2003 -06- 2 4
PCT/IN99/00052 - the fruits, have been widely used for preparation of hypoglycaemic pharmacological compositions.
The extracts juice of the fruit is known to exhibit hypoglycaemic properties and g often recommended to reduce the blood sugar levels in patients suffering from diabetes mellitus.
Any amount of polypeptide-p can be synthesised from this plant which is so easy to cultivate. :
In Indian Patent No. 136565, the “applicant has disclosed a method for the extraction of polypeptide-p from Momordica charantia. The dried and pulverized . fruits and tissue cultures of Momordica are separately extracted in ethanol and then mixed with cold ethanol and diethyl ether. Thereafter, needle-like crystals are formed by adding zinc in traces after 18 hr. The fruits-and cultures are separately crushed, homogenized in water, ethanol and concentrated sulfuric acid is added for adjusting pH and 03 to obtain flocculent precipitates.
This method had the following drawbacks: . 20 : 1. The use of alcohol in the extraction procedure was not practical due to its unavailability in large amount and the impurities present in it. ) 2. The use of raw material as fruits and tissue culture creates problems in : handling, uneconomically viable and the yield was very poor. :
The drawbacks of this patent were obviated in another Indian Patent No. 176040.
This patent discloses a process for extraction of a highly effective polypeptide-p by using hexane along with diethylether. Although the process developed and disclosed in above referred patent resulted in good yield, improved purity and high efficacy of the drug by removal of oil and sapogenins and other contaminants therefrom, . yet it had some drawbacks of which a few are given below: :
EE | 2 AMENDED SHEET 2003 -06- 24 iy WO 00/61619 PCT/INYY/uuls2
I. The purification of polypeptide-p was a cumbersome method due to the presence of interfering radicals as oil and sapogenins. 2. Use of diethylether in the extraction procedure was not practical due to its being highly inflammatory and involving high cost. 3. The. presence of pesticides / insecticides / urea and other contaminants : affected the purity of polypeptide-p. 4. The yield was not optimum.
US Patent No. 5484889 describes a plant protein useful for treatment of tumors and HIV infection. The protein has been obtained from the seeds of Momordica charantia. It is pertinent to note that this protein isolated and purified is a * ribosome inactivating protein and hence useful in tumor therapy. The processes described for the extraction of the protein involves use of solvents and the tedious process of chromotography, dialysis etc. In the processes described in this patent as well as in Indian patent No.176040, the yield, purity were low and had several contaminants. Accordingly, to obviate these and other drawbacks, the applicant has isolated a novel polypeptide-k having hypoglycaemic property from Momordica charantia and has also devised a novel process for extraction of the protein from the same source. y : 20 . )
Objects :
It is an object of the invention to provide a novel protein. o5 It is an object of the invention to provide a process for the extraction of protein from the seeds and fruits of Momordica charantia.
Another object is to prepare a novel hypoglyceamic composition using the said protein. | :
Yet another object of the invention is to provide hypoglyceamic composition for treatment of diabetes in human beings and animals. 3
AMENDED SHEE: 2003 -06- 2 4
In accordance with the above and other objectives, the invention provides novel polypeptide-k obtained from Momordica charantia, a process for the extraction of the said polypeptide-k and novel hypoglycaemic compositions employing the polypeptide of the invention.
Detailed description : 1 0 - . - .
Accordingly, the invention provides a method for the extraction of proteins fruit seeds from the seeds of Momordica charantia comprising the steps of: 1) grinding the dry seeds to a fine powder in a suitable mill, 1) treating the pulverized seeds with a mixture of non-polar solvents, : iii) dissolving the residual mass in about 80% aqueous acetone, iv) adjusting the pH upto 9.5 by adding suitable organic buffer like ammonium hydroxide, to
Vv) treating the supernatant layer with sulfuric acid, og Vi) collecting the flocculent precipitate of polypeptide-k and isolating the protein by selective crystallisation. Thereafter the protein is analysed by chromatography. . ‘
The novel protein polypeptide-k extracted from the seeds of Momordica charantia comprises amino acids including:
Amino acid pn Moles/mg® Molecular number 0.273
Thweomme 0.8
Serine [01% 0.305 19
Proline | 0.1% 10
Glycine | 025 19 [Alanine | 0240 15
Valine | 01m [Cysteine | 00s8 4
AMENDED SHEET p03 -06- 24
Phenylalanine 0.082 5 ee ose 4
NH, 0.431 (27) omit 166
TOTAL residues
Approximate molecular weight 18000 ‘
In one embodiment, the seeds of Momordica charantia are split, washed thoroughly with water 2-3 times to render it substantially free from impurities and dried under vacuum, before extraction of the protein. Cee -
In another embodiment, the solvents used comprise a mixture of acetone with hexane, taken in the ratio 3:1.
In one embodiment, thin glass plated (20 x 20) coated (0.4 mm to 0.5 mm thick) with silica gel G are activated at 100°C, the solution of insulin applied, the plates developed in n-butanol, water, acetic acid (12:5:2) dried, the single spot corresponding to standard insulin visualized by spraying nin-hydrin (0.25%) in acetone, isolated along with silica gel G from unsprayed plates, extracted in 50% i ethanol] buffered with ammonium hydroxide, filtered, the filtrate dried and pure white needle-like crystals formed. :
In yet another embodiment, when the analysis 1s carried out, the isolated substance is hydrolyzed alongwith the standard insulin, applied on paper chromatograms separately, developed, yielding same amino acids except glutamine being an extra amino acid in the polypeptide -k. : 5
AMENDED SHEET 5003 -06- 24
In another feature. the isolated substance and the standard insulin are hydrolyzed separately by 6 N HCI for 20 hours, dried. reconstituted in 50% ethanol, applied on Whatman No. | filter paper strips developed in /i-butanol, acetic acid, water ) (60:320:20), strips developed sprayed with 0.25% nin-hydrin in acetone, amino acids same as of the standard hydrolyzate except glutamine being extra intra in or polypeptide-k.
In the analysis is carried out, the seeds are extracted in hexaneacetone yielding a product which has the same melting point (234°C), Gel electrophoretic pattern of the accompanying drawings and number of amino acids of the standard insulin except glutamine being extra in polypeptide-k. ’
It may be noted that although most of the plant parts of Momordica contain the protein disclosed by the invention, in varying degrees the protein polypeptide-k is extracted from - the dry seeds.
The dried seeds are processed using hexane (food grade) along with acetone instead of ether as used in the process described in earlier Patent No. 176040. The process has resulted in high yield, improved purity and high efficacy of polypeptide by removal of undesired oils, flavonoids and sapogenins therefrom. *
Diabetes is a disease wherein glucose is not utilized as an energy source in the body such glucose remains at a high levels in the blood and eventually gets og excreted through urine. In some conditions, insulin secreted from beta cells of pancreas is insufficient or does not sufficiently fulfill its function.
Diabetes is generally classified into insulin-dependent diabetes (Type I diabetes) and noninsulin-dependent diabetcs (Type II diabetes). Type 1 diabetes is in the q0 state of lowering of the function of pancreatic beta cells resulting from hereditary cause, viral infection -etc. wherein insulin is substantially not secreted, and suddenly attacks mainly in the twenties to thirties. Although it is not sure. onset of type 11 diabetes in the forties or in cases with family history of diabetes, obesity, 6
AMENDED SHEET 2003 -06- 2 4
I stress. etc. In the case of type Il diabetes, since insulin is sufficiently secreted from pancreas but insulin resistance and glucose utilization are different from those of normal person, blood sugar is not returned to normal level in spite of hyperinsulinemia.
Diabetes is accompanied with numerous symptoms. Typical examples of such symptoms are polyuria, excessive drinking and polyphagia. That is, diabetic patients exhibit polyuria which is caused by excretion of glucose and excessive water through urine by the action of osmotic pressure originated from high blood glucose level, and therefore, complain of thirst caused by dehydration, which induces excessive drinking, and feels the empty of stomach to cause excessive intake of food. Diabetic patients cannot efficiently utilize glucose as an energy source and, instead, utilize protein and fat as preserved in the body, and this phenomenon is caught in a vicious circle to cause the reduction in body weight.
However, such phenomena are merely acute symptoms observed in the primary stage of diabetes. If diabetes becomes chronic by delay of treatment, chronic vascular diseases are induced as a complication. Thus, diabetic complications such as diabetic retinopathy (visual disturbance, blindness, retinal hemorrhage), oo diabetic nephropathy, diabetic peripheral neuropathy, etc. reduce general metabolic and sensory function of human body.
A number of medicines have been produced and tested act to lower blood sugar of a non-insulin dependent diabetics. However, the majority of these medicines have og one or more undesirable features, some of them have significant side effects for a large portion of the population, or a large dosage is necessary. Also, some of them reduce the blood sugar level too much so that they can only be used sporadically or they can be a threat to health, and others have possible toxicity. At present, there is no natural antidiabetic drug which is highly effective at lowering blood sugar, yet does not lower it to an unsafe level, and has no significant side effects.
“
According to the present invention, a pharmacologically active hypoglycaemic agent is produced in a simple and straightforward way using only the protein of the invention. It is relatively small amounts of the homeopathic medicine need be ingested in order to perform the desired function.
Herbal composition using the protein of the invention:
The protein extracted from Momordica charantia exhibits hypoglyceamic properties and accordingly compositions comprising the protein can be for the treatment of hypoglyceamia treatment in mammals. The protein obtained from
Momordica is in the form of an amorphous powder. The protein activates the inactive insulin and, thus, it can rejuvenate the pancreas depending upon the chronicity of the pathological condition of the individual. In fact, in course of time, it may act as a cure for diabetes. The applicant has conducted more than 500 experiments and confirmed that the single dose to about 12 mg of the protein at a time is quite effective. Accordingly, it is advisable that compositions containing the protein in single does should comprise about 12 mg of the protein.
Hypoglyceamic compositions using the proteins of the invention can be 9g formulated in a variety of physical forms such as tablets, injections, edible products. For preparation of a tablet, about 12 mg of the protein is mixed with pharmacologically acceptable carriers suitable for consumption. The pharmacologically acceptable carrier must be of sufficient purity and low toxicity.
Edible products like biscuits, chewing gums etc, which are not instantly 55 swallowed can be prepared. In all such preparations, the content of the protein is about 12 mg. It is found that salt biscuits prepared using the protein of the invention are very popular with diabetics.
It is pertinent to note that the hypoglyceamic composition of the invention is to be consumed 10 minutes before meals, at least 4 times a day. The most important aspect is that the tablet or the hypoglyceamic composition should only be chewed and should not be swallowed instantaneously.
EN
In a feature of the invention, the hypoglyceamic composition herein described has no side effects. It can be consumed without restricting the use of other therapies.
The invention is described in detail with reference to the following illustrative examples. Several modifications that may be apparent to those in the art are deemed to be included within the scope of the invention.
Example 1 (Protein preparative example)
Extraction of protein from Momordica charantia L: 100 gms of dry seeds were taken from the ripe fruits of Momordica charantia L. The seeds were split manually. The split seeds were then thoroughly washed with water 3-4 times to render them substantially free of all impurities. The split seeds were then dried "15 under vacuum and pulverized to a fine powder using a milling device. Any other conventional device may also be used.
The fine powder was then treated with acetone hexane solvent mixed in the ratio 1:2 and the residual mass was dissolved in 20% acetone. The pH was adjusted to 50 9.5 by adding ammonium hydroxide / organic buffer, the supernatant thus obtained was buffered with H,SO,4 to adjust pH3 for obtaining flocculent precipitate which were collected and crystallised with zinc acetate.
Thin glass plated (20 x 20 cm) coated (0.4 mm to 0.5 mm thick) with silica gel G (Kieselgel G nach Stahl; E. Merck) were activated at 100°C for half an hour. The solution containing the isolated substance was applied 1 cm above the edge of the plates were run in an organic solvent mixture of n-butanol, water and acetic acid (12:5:2). The developed plates were dried at room temperature and sprayed with 0.25% ninhydrin in acetone. The ninhydrin positive spots (R = 0.19) of the isolate corresponding to insulin were collected from about 200 unsprayed plates along with the silica gel G and extracted with 50% ethanol buffered with ammonium hydroxide. The extract was filtered and dried in vacuo. Pure colorless crystals thus obtained were weighed (3 g/100 gram dry weight of seeds).
The melting point of the purified compound (232° - 235°C) as well as the mmp (254°C) were determined. The melting point of the standard insulin was recorded as 233°C. :
The standard sample of insulin as well as the isolated polypeptide-k were hydrolyzed under reflux with 6N HCI for 20 hours separately. The hydrolyzates were filtered, dried, reconstituted separately in 50% ethanol and applied on strips of Whatman No. | paper. The paper strips were run in an organic solvent mixture of n-butanol, water and acetic acid (60:20:20). The hydrolyzates of both the isolated , and the standard insulin were also applied separately along with the known amino acids (hydroxylysine, methione, hydroxyproline and trytophan). The various developed chromatograms were sprayed with 0.25% ninhydrin in acetone. The isolated : compound had 18 amino acids; glutamine is the extra amino acid in polypeptide-k. _
Hydroxylysine, hydroxy-proline and tryptophan were found to be absent from the hydrolyzate of the isolated polypeptide-p as well as of the standard. hydrolyzate which gave an indication that the isolated polypeptide-p is nearly identical with that of the insulin except glutamine being an extra-amino acid in polypeptide-k. Eighteen amino- acids were observed in polypeptide-k as compared to 17 amino acids in polypeptide-p.
Disc eletrophoresis was carried out (10% SDS Biophore Gel, run in tris buffer, operating pH 6:1, 3% acetic acid in lower cell; 90 V, mA 2.5 per tube; Bromophenol blue tracking dye). Samples of the crystallized isolate and bovine insulin containing dithiothreltol and EDTA, injected and run for 7 hr. Gel collected from the tubes were stained (0.05% coomassie Brilliant Blue R-250 in 7% aqueous acetic acid) and washed with 10% acetic acid. Electrophoretic pattern of both the isolate and the bovine insulin were nearly identical as shown in figure 1 of the: accompanying drawings. Immuno assays of popypeptide-p did not show any cross reaction when tested with bovine insulin. 10 AMENDED SHEET 2003 -05- 24
EK WO 00/61619 PUT/INYY100052
Sublingual administration of the isolate showed positive and highly effective hypoglycaemic activity. When five hundred diabetic patients were treated (Table 1) no side effects of the drug were observed. Neuropathy, lethargieity, hypoglycaemia were not reported in these patients even when the drug was administered for a period of 2-4 years. At the same time, sugar level in the blood come down appreciably in one month time. The results are shown in table I.
Example 2 (Extra ction of protein from Momordica charantia L.) 200 gms of dry seeds were taken from the ripe fruits of Momordica charantia L.
The seeds were spilt manually. The split seeds were then thoroughly washed with water 3-4 times to render them substantially free of all impurities. These seeds were then dried under vacuum and pulverized to a fine powder using a milling device. Any other conventional devices may also be used. - The fine powder was then treated with acetone hexane solvent mixed in the ratio 1:2. Thin glass plated (20 x 20 cm) coated (0.4 mm to 0.5 mm thick) with silica Co
NB gel G (Kieselgel G nach Stahl; E. Merck) were activated at 100°C for half an hour.
The solution containing the isolated substance was applied 1 cm above the edge of the plates were run in an organic solvent mixture of n-butanol, water and acetic acid (12:5:2). The developed plates were dried at room temperature and sprayed with 0.25% ninhydrin in acetone. The ninhydrin ‘positive spots (R = 0.19) of the isolate corresponding to insulin were collected from about 200 unsprayed plates along with the silica gel G and extracted with 50% ethanol! buffered with ammonium hydroxide. The extract was filtered and dried in vacuo. Pure colorless crystals thus obtained were weighed (3 g/100 gram dry weight of seeds).
The melting point of the purified compound (232° - 235°C) as well as the mp (234°C) were determined. The melting point of the standard insulin was recorded as 233°C. ; AMENDED SHEET. . 2003 -06- 24
The standard sample of insulin as well as the isolated polypeptide-p were hydrolyzed under reflux with 6N HCI for 20 hours separately. The hydrolyzates were filtered, dried, reconstituted separately in 50% ethanol and applied on Strips of Whatman No. 1 paper. The paper strips were run in an organic solvent mixture of n-butanol, water and acetic acid (60:20:20). The hydrolyzates of both the isolated and the standard insulin were also applied separately along with the known amino acids (hydroxylysine, methione, hydroxyproline and trytophan). The various developed chromatograms were sprayed with 0.25% ninhydrin in acetone. The amino acids of the hydrolyzate of the standard coincided exactly with those of the hydrolyzate of the isolated compound except methionine and glutamine being extra amino acid in isolated polypeptide-k. Hydroxylysine, hydroxy-proline and tryptophan were found to be absent from the “hydrolyzate of the isolated polypeptide-k as well as of the standard hydrolyzate which gave an indication that . the isolated polypeptide-k is nearly identical with that of the insulin. The polypeptide-k showed 18 amino acids. oo Amino acid 1 Moles/mg? Molecular number 0273 | 17 |" [Threonine [Tous | 87 [Serine 0793 0.305 (Proline 35 [0
Glycine 055 | 1g
Alanine 0550 [1s
Valine oa 11] [VaCysteine 058 0.031
Tsolewine 1 g11
Lene 3
Tyrosine 001g |]
Phenylalanine 0.082 5
Histidine | o.6
Lysine op 5 (Arginine 0061 | 0
Glutamine 0.182 TT 12
AMENDED SHEET 79p3 -06- 74
- PCT/IN9Y/00052
TOTAL residues
Approximate molecular weight 18000 : Disc eletrophoresis was carried out (10% SDS Biophore Gel, run in tris buffer, operating pH 6.1, 3% acetic acid in lower cell; 90 V, mA 2.5 per tube;
Bromophenol blue tracking dye). Samples of the crystallized isolate and bovine insulin containing dithiothreltol and EDTA, injected and run for 7 hr. Gel collected from the tubes were stained (0.05% coomassie Brilliant Blue R-250 in 79 aqueous acetic acid) and washed with 10% acetic acid. Electrophoretic pattern of both the isolate and the bovine insulin were nearly identical as shown in figure 1 of the accompanying drawings. Immuno assays of popypeptide-k did not show any cross reaction when tested with bovine insulin. ‘Below are representative examples of case studies, wherein patients have been administered the hypoglyceamic composition of the invention. All these patients were afflicted with diabetes mellitus, though the chronicity varied from case to case. The patients were advised to consume good quality food substantially free from starch, and containing at least 1 fruit. The patients were also advised exercise besides use of the composition of the invention. Most of the patients took drugs like Diaonil/ Glyciphate/ Glynase/ DBI/ Euglucon/ Dimicron or combination of 8lyciphage and glynase before commencement of the treatment.
Gradual fall in blood sugar level of the patients was observed after one week to 40 days and then it came to normal. Continued intake of the composition of the invention varied from 6 months to 3 years as four doses 10-15 minutes before each meal sublingually. In patients with blood sugar level from 355 or more diaoni] in doses of 2 (1+1) or 1 (% + /2) was supplemented with the dose of the composition (morning, evening). Diaoni] was withdrawn completely after 15 days. 13 «ENDED SHEET 2003 -06- 24
Case studies . I. Mr. Vivek Mukherjee. aged 18, complained of leg pain, excessive thirst for
N walter, frequent urination and blurring vision. Upon examination, his blood sugar
N 5 level was found to be 425 mg/dl as pp and fasting as 209 mg/dl. No oral drug worked effectively. The patient was advised to consume the hypoglycaemic composition of the invention (12 mg/dl/dose and 4 doses per day. Each dose was consumed 10 minutes before every meal without any liquid or solid) along with - : diaonil (1+1+1). This reduced the blood sugar level considerably. Diaonil was 10 reduced to half after one month and later withdrawn completely and surprisingly the blood sugar level was reduced to 114 mg/dl (pp) after 2 months. The patient is now completely dependant on the composition of the invention and is maintaining normal blood sugar level with no side effects. 3 2. Another patient, Prof. K.P. Mishra, aged 71 years, was a chronic diabetic with a blood sugar level of 305 mg/dl. He was on insulin (18 units/day). The patient was advised to consume the composition of the invention 4 times. He is maintaining normal blood sugar for the last two years. 3. Mr. D.P. Gaur, aged 60 years, was a chronic diabetic since last 10 years. He developed neuropathy and lethargicity in the body even on taking 60 units of insulin. There were symptoms of high blood pressure and high triglyceride levels.
This patient started taking the formulation of the invention 4 times a day alongwith the insulin which was reduced to Yy. The blood sugar level was reduced. The insuling dose was gradually reduced and finally withdrawn and now the patient is maintaining normal blood sugar level and keeping fit with 4 doses of formulations of invention. 4. Mrs. Rashmi Geha, 46 years old, developed symptoms, which on examination of blood profile confirmed (haemoglobin-glycosilation test) the diabetes (320 mg/dl). She started taking the powder of the invention and has been maintaining normal blood sugar levels She has not taken any other oral drug. a d WO 00/61619 PCT/IN99/00052 5. Mr. Banerjee. 70 years old, was a chronic patient (15-20 years) and with a high blood pressure. high triglyceride and cholesterol levels. He took the powder for 3 years, four doses per day of formulation of the invention. This kept normal blood sugar levels and controlled levels of blood pressure and cholesterol levels.
Tablel:Effect of Gourdin (polypeptide-k) on blood sugar level ‘in patients with diabetes mellitus.
No. of subjects Diabetes duration “Range of blood "Polypeptide-k (yrs.) | sugar level mg/dl | effect Mean mg/dl (post prantl) Sfall in blood sugar level (after 207 days). : 160-200 120-110 250 [610 210350 | 150090 100 [Ws 355450 | 250270
Ls [1520 | 460500 | am
The following are the advantages 1. The polypeptide-k was found to be more effective than polypeptide-p isolated by the process claimed in earlier patent no. 176040. The extraction procedure for polypeptide-k was improved and made more effective. 5 1 2. The polypeptide-k was highly effective hypoglyceamic drug when administered sublingually. . 3. The cholesterol level including total cholesterol, HDL, LDL, VLDL and triglyceride iE go down to normal using this drug as an anti-diabetic remedy. 4, Symptoms as leg pain, lethargy did not appear when more than 500 patients of 2-4 years of duration with this drug was given. This invention as described in the example is merely illustrative in nature and not intended to restrict the scope of the invention.
The origin of the hypoglycaemic composition and its effects : 1. It is the protein extract of "Karela" / Bittergourd / Momordica charantia L. 2. Combustion point /mp of Gourdin or polypeptide-k was found to be 232° C (£)2° C. 1s } .
AMENDED SHEET po oc,
Sap 3. When analyzed with amino acid analyzer the hydrolyzate showed 18 amino acids (Fig. 1). 4. A single electrophoretic band was observed which on scanning showed a single main peak of pure gourdin (Fig. 2).
OS. Bio-immunoassays of polypeptide-k were found to be negative against insulin. 6. Pharmacological study revealed a significant blood-sugar-lowering,. 7. Polypeptide-k is completely insoluble in water. 8. It physically can be tested with nin-hydrin which on heating the soluble fraction turned yellow in colour turning purple later. 9. On sequencing the polypeptide fraction, the first terminal was found to be free (Fig. 3). 10. The hypoglycaemic composition of the invention activates the inactive insulin present in the blood and hence, it cures the disease, the time factor _ depends on the chronicity of the illness. 11. If hereditary, a single dose by a normal person acts as preventive dose.
B 12... If cholestrol level is high, its intake reduces the level. 13. High Triglyceride level is also reduced. } EE 14. ) Pain and inflammation of the joints is either eliminated or reduced. oo 15." Its intake gives a feeling of normalcy to the diabetic patient. 16. No other side effects were observed. . 16
AMENDED SHEET 2003 -06- 24 oY
Claims: 1. A novel protein (polypeptide-k)extracted from Momordica charantia comprising amino acids including;
Amino acid u Moles/mg? Molecular number 0.138 0.195 0.159 [| 10 0.225 0.240 0.174 0.058 0.031 0.116 0.207 0.016
Phenylalanine 0.082 0.066 0.209 0.161
NH; 0.431
TOTAL
Aapproximate molecular weight 11000 2. A process for the extraction of a novel protein (polypeptide-k) from
Momordica charantia comprising the steps of: 1. grinding the dry seeds of Momordica charantia, il. treating the pulverized seeds with a mixture of non-polar solvents, iil. dissolving the residual mass in about 80% aqueous acetone, : iv. adjusting the pH upto 9.5 by adding suitable organic buffer like ammonium hydroxide,
v
V. treating the supernatant layer with sulfuric acid after adjusting the pH to 3, and vi. collecting the flocculent precipitate of polypeptide-k and isolating the protein by selective crystallization. 3. A process as claimed in claim 2 wherein the protein is extracted from the fruit = and/or seeds of Momordica charantia 4. A process as claimed in claim 2, wherein the seeds of Momordica charantia are split, washed thoroughly with water 2-3 times to render it substantially free from impurities and dried under vacuum, before extraction of the protein. 5. A process as claimed in claim 2 wherein the non-polar solvents used comprise a mixture of acetone with an aromatic or aliphatic hydrocarbon selected from the group of benzene, hexane, petroleum ether and ethyl ether. 6. A process as claimed in claim 2 wherein the ratio of the aliphatic or aromatic hydrocarbon in the non-polar solvent mixture is 2:1. 7. Use of the protein extracted from Momordica charantia to manufacture a hypoglycemic composition useful in the treatment of diabetes mellitus.
Claims (7)
1. A novel protein named as polypeptide-k, isolated with 100% purity from Momordica charantia, comprising the following 18 amino acids: Amino acid 4 Moles/mg® Molecular number [Threomime 0.3 | 8.7 Serine Toes | 1 Glutamic acid 0.305 | 15 [Proline 0.355 | 10 Glycine Tos | 15Alanine 0240 | 15 Valine ova | 11 4 Cysteine | 008s | 3% Methionine | 0031 | 7 [Isoleucine 5a | 7] [Leucine [0307 | 13 [Tyrosine 508 [1 Phenylalanine [Histidine | oe | 4 (Tysfhe T0305 | 13 Arginine 0.161 10 Glutamine 0.182 21 NH; 0.431 TOTAL Approximate molecular weight 18,000 Said polypeptide-k is water insoluble but partially soluble at pH 9.5 and said polypeptide-k is not injectible but capable of sub-lingual administration.
2. A process for the extraction of a novel protein (polypeptide-k) from Momordica charantia comprising the steps of: 19 AMENDED SHEET (ARTICLE 19)
i. grinding the dry seeds of Momordica charantia, w ii. treating the pulverized seeds with a mixture of non-polar solvents,
iii. dissolving the residual mass in about 80% aqueous acetone,
iv. adjusting the pH upto 9.5 by adding suitable organic buffer like ammonium hydroxide,
Vv. treating the supernatant layer with sulfuric acid after adjusting the pH to 3, and vi. collecting the flocculent precipitate of polypeptide-k and isolating the protein by selective crystallization.
3. A process as claimed in claim 2 wherein the protein is extracted from the fruit and seeds of Momordica charantia.
4. A process as claimed in claim 2, wherein the seeds of Momordica charantia are split, washed thoroughly with water 2-3 times to render it substantially free from impurities and dried under vacuum, before extraction of the protein.
5. A process as claimed in claim 2 wherein the non-polar solvents used comprise a mixture of acetone with an aromatic or aliphatic hydrocarbon selected from the AMENDED SHEET (ARTICLE 19)
‘ of group of benzene, hexane, petroleum ether and ethyl ether.
6. A process as claimed in claim 2 wherein the ratio of the aliphatic or aromatic hydrocarbon in the non-polar solvent mixture is 2:1.
7. Use of the protein polypeptide-k extracted from Momordica charantia for curing or treating diabetes mellitus by sub-lingual administration of polypeptide- k to a patient. +21 AMENDED SHEET (ARTICLE 19)
he STATEMENT UNDER ARTICLE 19 Khanna P et al: "Hypoglycaemic activity polypeptide-p from a plant source" Journal of Natural products, xx xx Vol 44, pages 648-655. This citation is the inventor's own previous investigation and work. Inadvertently, at the time of filing, the details of polypeptide-p which is referred in the citation has been repeated in the claim. In fact, the Applicant has isolated a novel protein called "polypeptide-k". This polypeptide-k differs from polypeptide-p in the following respects:
1. The polypeptide-k has 18 amino acids whereas polypeptide-k has only 17 amino acids. The extra amino acid present in polypeptide-k is glutamine.
2. The approximate molecular weight of polypeptide-k is 18,000 units whereas the weight of polypeptide-p is 11,000.
3. Polypeptide-k has a free N-terminal whereas polypeptide-p has no such terminal.
4. Polypeptide-k is not water soluble whereas polypeptide-p is water soluble.
h WO 00/61619 PCT/IN99/00052
- 5. Polypeptide-k is not injectible to a patient and can be administered only through sub-lingual route whereas polypeptide-p is injectible to a patient. Polypeptide-k is a different protein than polypeptide-p. Polypeptide-k has been identified recently by the inventor and has different properties. It is possible that a plant may have different proteins of which the applicant has now isolated and characterized a novel protein named as polypeptide-k. The process claimed in claim 2 has not been envisaged in the citation. This process has been specifically devised to . extract polypeptide-k which is partially soluble at pH 9.5. The sequence of steps and the ingredients used in the . present invention are different from the process disclosed in the citation. The other citations are graded "A" as being relevant to the technological background of the invention.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN560DE1999 IN188673B (en) | 1999-04-13 | 1999-04-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200108326B true ZA200108326B (en) | 2003-04-29 |
Family
ID=29765109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200108326A ZA200108326B (en) | 1999-04-13 | 2001-10-10 | Protein/polypeptide-k obtained from momordica charantia and a process for the extraction thereof. |
Country Status (2)
Country | Link |
---|---|
IN (1) | IN188673B (en) |
ZA (1) | ZA200108326B (en) |
-
1999
- 1999-04-13 IN IN560DE1999 patent/IN188673B/en unknown
-
2001
- 2001-10-10 ZA ZA200108326A patent/ZA200108326B/en unknown
Also Published As
Publication number | Publication date |
---|---|
IN188673B (en) | 2002-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4353982B2 (en) | Synergistic composition for the treatment of diabetes | |
JP5538611B2 (en) | Maillard reaction inhibitor | |
DE69729125T2 (en) | TROPONIN SUB-UNITS AND FRAGMENTS FOR USE AS INHIBITORS OF ANGIOGENESIS | |
MXPA04011089A (en) | Fenugreek seed bio-active compositions and methods for extracting same. | |
JPH03167129A (en) | Method for processing allium plant | |
US20090208595A1 (en) | Extract of plant Dendrobii caulis and preparing process thereof | |
AU774836B2 (en) | Protein/polypeptide-K obtained from momordica charantia and a process for the extraction thereof | |
RU2668135C1 (en) | Pharmaceutical composition for the treatment and prevention of degenerative neurological disorders which comprises, as an active ingredient, a mixed root extract of the tree peony root, the root of dahuric angelica and the root of thorowax or its fraction | |
DE60124532T2 (en) | NEW POLYPEPTIDES FROM BEEKE POISON AND METHOD FOR THEIR USE | |
KR20200120884A (en) | A Pharmaceutical Composition For Blocking AGEs Production And Promoting AGEs Decomposition Comprising Extracts Of Juglans Mandshurica Maxim., Its Fractions, Or A Physiologically Active Compound Derived Therefrom As Active Ingredient | |
ZA200108326B (en) | Protein/polypeptide-k obtained from momordica charantia and a process for the extraction thereof. | |
EP1331939A1 (en) | Murraya koenigii extracts for treating asthma | |
DE60036638T2 (en) | USE OF COLOSTRININ, THEIR PEPTIDE COMPONENTS AND THEIR ANALOGUE FOR PROMOTING NEURONAL CELL DIFFERENTIATION | |
US20090053332A1 (en) | Compositions for diabetes treatment and prophylaxis | |
DE60207257T2 (en) | HETEROCARPIN, A PROTEIN BINDING HUMANES GHRH | |
DE19543628A1 (en) | Human circulating peptide with insulinotropic activity (GCAP-II- (89-112), (guanylyl cyclase C activating peptide II) and its GCAP analogues, in particular GCAP-I- (99-115), its use as a pharmacological Active ingredient and use of its principle of action to provide new GC-C-dependent insulinotropic active ingredients | |
EP0273121B1 (en) | Oligopeptides from ox blood | |
JPH1045613A (en) | Interleukin 4 production inhibitor | |
DE69736828T2 (en) | ANTIMICROBIAL PROTEIN | |
WO1992015606A1 (en) | New inhibitors of endothelial cell proliferation | |
Tauqueer et al. | ANTIDIABETIC ACTVITY OF WHEAT GRASS JUICE | |
WO2014195975A2 (en) | Plant fractions having anti-pathogenesis properties. | |
KR20220119230A (en) | A composition for preventing or improving muscular disorders comprising extracts of undaria pinnatifida, pomelo, and wheat germ | |
JP2021019532A (en) | Blood-brain barrier protective agent | |
US20080167221A9 (en) | Heterocarpine, a plant-derived protein with anti-cancer properties |